Compare Goodyear Tire & Rubber Co (GT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Inovio Pharmaceuticals Inc — how do they compare? Goodyear Tire & Rubber Co trades at $7.11 (market cap $1.94B), while Inovio Pharmaceuticals Inc trades at $1.13 (market cap $96.26M). The key difference: Goodyear Tire & Rubber Co is far larger — about 20.2× Inovio Pharmaceuticals Inc's market cap, and Goodyear Tire & Rubber Co is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| GT | INO | |
|---|---|---|
Market Cap | $1.94B | $96.26M |
Sector | Consumer Cyclical | Health |
52-Week High | $11.54 | $2.87 |
52-Week Low | $5.58 | $1.05 |
Enterprise Value | $9.25B | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GT trades at $7.18, up 7.81% today, with a bullish technical signal and moving average alignment. The stock shows attractive valuation ratios (P/E 4.69, P/B 0.64) but faces profitability challenges, with a net income margin of -11.64% in 2025. Recent news includes a shift to the S&P SmallCap 600 and a $1.05 billion senior notes offering. Q1 2026 earnings beat estimates, yet revenue trends are declining.
Outlook: Deep value metrics and analyst consensus target of $8.75 suggest upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Investors should weigh low valuation against operational headwinds and macroeconomic sensitivity.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
